1] Molecular Immunology Unit, Hospital Universitario Puerta de Hierro, Madrid, Spain [2] Current addresses: Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Mol Ther Nucleic Acids. 2013 May 21;2(5):e93. doi: 10.1038/mtna.2013.19.
A human single-chain variable fragment (scFv) antibody library was expressed on the surface of human T cells after transduction with lentiviral vectors (LVs). The repertoire was fused to a first-generation T cell receptor ζ (TCRζ)-based chimeric antigen receptor (CAR). We used this library to isolate antibodies termed CARbodies that recognize antigens expressed on the tumor cell surface in a proof-of-principle system. After three rounds of activation-selection there was a clear repertoire restriction, with the emergence dominant clones. The CARbodies were purified from bacterial cultures as soluble and active proteins. Furthermore, to validate its potential application for adoptive cell therapy, human T cells were transduced with a LV encoding a second-generation costimulatory CAR (CAR(v2)) bearing the selected CARbodies. Transduced human primary T cells expressed significant levels of the CARbodies-based CAR(v2) fusion protein on the cell surface, and importantly could be specifically activated, after stimulation with tumor cells. This approach is a promising tool for the generation of antibodies fully adapted to the display format (CAR) and the selection context (cell synapse), which could extend the scope of current adoptive cell therapy strategies with CAR-redirected T cells.Molecular Therapy-Nucleic Acids (2013) 2, e93; doi:10.1038/mtna.2013.19; published online 21 May 2013.
经慢病毒载体(LV)转导后,人源单链可变片段(scFv)抗体文库被表达在人 T 细胞表面。该文库与第一代 T 细胞受体 ζ(TCRζ)为基础的嵌合抗原受体(CAR)融合。我们使用这个文库在原理验证系统中分离出了能够识别肿瘤细胞表面抗原的抗体,称为 CARbody。经过三轮激活-选择,出现了明显的库限制,优势克隆出现。CARbody 作为可溶性和活性蛋白从细菌培养物中纯化出来。此外,为了验证其用于过继细胞治疗的潜在应用,我们用人源 Lv 转导编码带有所选 CARbody 的第二代共刺激 CAR(CAR(v2))的 T 细胞。转导的人原代 T 细胞在细胞表面表达了显著水平的基于 CARbody 的 CAR(v2)融合蛋白,重要的是,在用肿瘤细胞刺激后,可以被特异性激活。这种方法是一种很有前途的工具,可以生成完全适应展示形式(CAR)和选择环境(细胞突触)的抗体,从而扩展 CAR 重定向 T 细胞过继细胞治疗策略的范围。《分子治疗-核酸》(2013 年)2,e93;doi:10.1038/mtna.2013.19;在线发表于 2013 年 5 月 21 日。